Infected : Actualité Infected en direct - P2 | Bourse Reflex
Accueil > Tags > Infected

  • Toutes les actualités en rapport avec « Infected »

02/07 18:15 Infected - Genticel CFO, Martin Koch, Appointed CEO to Replace Benedikt Timmerman during Temporary Medical Leave of Absence

16/06 07:00 Infected - Genticel Receives FDA Clearance of IND Application for U.S. Phase 1 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

01/06 07:00 Infected - Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform

21/05 18:00 Infected - Documents Available for Annual General Meeting of Shareholders

28/04 19:00 Infected - Business Update - First Quarter 2015

23/04 18:00 Infected - Genticel to Participate in SmallCap Event on April 27 - 28 in Paris, France

20/04 18:40 Infected - Genticel to Present Further Promising Pharmacology In-Vivo Results of its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (ProCervix), at AACR Annual Meeting 2015

09/04 19:20 Infected - Genticel strengthens management team and appoints Valerie Leroy as Senior Director, Corporate Communications and Investor Relations

01/04 17:00 Infected - 2014 Reference Document Available with Annual Financial Report

06/03 18:00 Infected - Implementation of a Programmed Trading Mandate

02/03 19:00 Infected - 2014 Annual Results

05/02 16:30 Infected - Genticel presents pipeline development in EUROGIN congress held in Seville, Spain - 4 to 7 February 2015

02/02 18:30 Infected - Genticel licenses Vaxiclase platform to Serum Institute of India for use in pertussis vaccines

27/01 19:20 Infected - Business Update - Fourth Quarter 2014

26/01 20:15 Infected - Genticel to continue per protocol its Phase 2 clinical study with ProCervix after 2nd review by the DSMB

22/01 19:30 Infected - Genticel announces its financial communication calendar for 2015

03/10 20:05 Infected - Apricus Biosciences Announces Korean Patent Approval for MycoVa(TM) for Nail Fungus

27/06 16:00 Infected - Apricus Biosciences Reports Reanalysis of Its U.S. Phase III Trials for MycoVa(TM) Showing Drug is Effective in Mycological Cure Resulting in Eradication of Nail Fungus

01/03 15:15 Infected - Apricus Biosciences Announces Expanded European Patent Coverage for MycoVa(TM) for Nail Fungus

19/01 17:45 Infected - Apricus Biosciences Reports Additional Analysis Showing That MycoVa(TM) is as Effective for the Treatment of Nail Fungus as the Current European Standard of Care for Topical Therapy, Loceryl(R)